



Market Announcement

28 March 2024

Osteopore Limited (ASX: OSX) – Suspension from Quotation

Description

The securities of Osteopore Limited ('OSX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSX, pending the release of its Annual Report.

Issued by

ASX Compliance

Nicholas Mountain
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Request for voluntary suspension

28 March 2024: Osteopore Limited (**ASX: OSX**) (“**OSX**” or the “**Company**”) hereby requests the voluntary suspension of its securities from the commencement of trading on Thursday, 28 March 2024.

The Company provides the following information regarding this request:

1. the voluntary suspension is requested due to unexpected delays in completing the 31 December 2023 Annual Report due to compiling information requested by the Company’s auditors. The Directors do not consider that trading of the Company’s securities should occur while the Annual Report remains un-lodged.
2. it anticipates the voluntary suspension will remain in place until the earlier of the commencement of normal trading on Tuesday, 30 April 2024, or until the 31 December 2023 Annual Report is lodged with the ASX.
3. the Company is not aware of any reason why the voluntary suspension request should not be granted, or of any other information necessary to inform the market about the suspension.

This announcement dated 28 March 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au

